Symbol Lookup from Yahoo Finance

Trending Tickers

Symbol	Name	Last Price	Change	Change %
PLTR	Palantir Technologies Inc.	80.55	+6.34	+8.54%
SPOT	Spotify Technology S.A.	460.88	+6.72	+1.48%
NVO	Novo Nordisk A/S	85.00	-18.44	-17.83%
NQ=F	Nasdaq 100 Dec 24	21,712.00	+145.50	+0.67%
RUM	Rumble Inc.	7.19	-0.08	-1.10%
YM=F	Mini Dow Jones Indus.-$5 Dec 24	43,453.00	+137.00	+0.32%
TLRY	Tilray Brands, Inc.	1.2600	+0.1000	+8.62%
ES=F	E-Mini S&P 500 Dec 24	6,029.00	+27.25	+0.45%
IONQ	IonQ, Inc.	44.42	+6.66	+17.64%
1398.HK	ICBC	5.040	+0.200	+4.13%
EDBL	Edible Garden AG Incorporated	0.2377	+0.0923	+63.48%
S08.SI	SingPost	0.5100	-0.0500	-8.93%
LCID	Lucid Group, Inc.	3.0200	+0.3900	+14.83%
BTC-USD	Bitcoin USD	94,901.38	-1,666.49	-1.73%
IIPR	Innovative Industrial Propertie	73.66	-21.68	-22.74%
KC	Kingsoft Cloud Holdings Limited	9.58	+1.18	+14.05%
^N225	Nikkei 225	39,161.34	+459.44	+1.19%
NOVO-B.CO	Novo Nordisk B A/S	589.20	-154.00	-20.72%
TCSG	The Container Store Group, Inc.	0.3200	-0.0300	-8.57%
EXR	Extra Space Storage Inc	147.00	+4.65	+3.27%
MYSZ	My Size, Inc.	4.2500	+2.8900	+212.50%
LUNR	Intuitive Machines, Inc.	13.57	+0.79	+6.18%
0939.HK	CCB	6.390	+0.170	+2.73%
BTC=F	Bitcoin Futures,Dec-2024	95,155.00	-1,445.00	-1.50%
NG=F	Natural Gas Jan 25	3.8880	+0.1400	+3.74%

Related News

The Container Store files for Chapter 11 bankruptcy

The Container Store couldn't keep up as consumers turned to Amazon, focused on essential goods and pulled back on big-ticket items.

Yahoo Finance 3 hours ago

TCSG

COST
Elon Musk, RFK Jr., Dr. Oz, and the coming clash over Ozempic

Biden officials recently proposed allowing Medicare to start covering GLP-1 medications to treat obesity. It's unclear whether Trump's administration will see it through.

Yahoo Finance 4 days ago

NONOF

NVO
Top trending global stocks of 2024

Here are the stocks that have reflected the key market trends of 2024 and have been closely watched by investors.

Yahoo Finance UK 1 hour ago

TM

TOYOF
Singapore Post Shares Slide After CEO Fired Over Whistleblower Report

(Bloomberg) -- Singapore Post Ltd. shares slumped by the most in more than four years after the firm fired its chief executive officer and a number of other senior executives following allegations related to its international e-commerce logistics parcels business.Most Read from BloombergReviving a Little-Known Modernist Landmark in BuffaloThe Architects Who Built MiamiHo Chi Minh City Opens First Metro Line After Years of DelayNew York’s Congestion Pricing Plan Still Faces Legal HurdlesNew York

Bloomberg 6 hours ago

SPSTY
Donald Trump’s Agenda Has New Enforcers: Charlie Kirk and a Legion of Influencers

On podcasts, posts and college campuses, conservatives push their worldview and the president-elect’s policies.

The Wall Street Journal 7 hours ago

RUM

RUMBW
Singapore Post fires CEO over handling of whistleblower report

The alleged misconduct reported by the whistleblower related to several employees who worked in the company's international e-commerce logistics parcels business, the company said in a statement, without giving further details. CEO Vincent Phang, the chief of the company's international business unit Li Yu, and Chief Financial Officer Vincent Yik had been dismissed after the company found they had been "negligent" in handling the case and misrepresented it before an audit committee, it added. Chair Simon Israel will oversee senior management of Singapore Post in the interim.

Reuters 13 hours ago

SPSTY
We're Interested To See How IonQ (NYSE:IONQ) Uses Its Cash Hoard To Grow

We can readily understand why investors are attracted to unprofitable companies. By way of example, IonQ ( NYSE:IONQ...

Simply Wall St. 17 hours ago

IONQ

IONQ-WS
Is Merck the Next Big Weight-Loss Stock?

Merck (NYSE: MRK) is hungrily looking to take a bite out of the weight-loss drugs market. Merck on Dec. 16 said it had just inked a license agreement with a Chinese biopharma company called Hansoh Pharma that could presage its merits as a weight-loss stock in the coming years. Per the terms of that deal, Merck will get the exclusive worldwide rights to develop and then sell HS-10535, a preclinical-stage candidate that could potentially be useful for treating a few high-profile cardiometabolic disorders, including obesity and perhaps type 2 diabetes.

Motley Fool 19 hours ago

NVO
The Investing Cult Fueling MicroStrategy’s Ascent: ‘Have Fun Staying Poor’

The rally has been propelled by a group of rabid followers who are mixing songs, pouring whisky and spending hundreds of hours researching the stock.

The Wall Street Journal 20 hours ago

MSTR

PLTR
Palantir Technologies (PLTR) Extends $400M Partnership with U.S. Army to Enhance Data and AI Capabilities

We recently published a list of 10 Buzzing AI Stocks on Latest News and Ratings. In this article, we are going to take a look at where Palantir Technologies Inc. (NASDAQ:PLTR) stands against other buzzing AI stocks on latest news and ratings. Predictions of artificial intelligence reaching human-level intelligence have been made for over 50 […]

Insider Monkey yesterday

PLTR
Tilray's CEO Makes a Bold Prediction: Is the Stock a Buy?

It's not a secret: The cannabis industry has been a major disappointment since Canada legalized recreational use in 2018. Tilray's CEO, Irwin Simon, recently made a bold prediction along those lines. Is legalization on the way in the U.S.?

Motley Fool yesterday

TLRY
Novo obesity data positive for Eli Lilly and Amgen, says UBS

UBS analyst Trung Huynh says Novo Nordisk’s (NVO) CagriSema Phase 3 topline obesity data “underwhelmed,” a positive read-through to Eli Lilly (LLY) and Amgen (AMGN). CagriSema achieved an average weight loss of 20.4%, below Novo’s prior guidance of 25% and inferior to Lilly’s tirzepatide at a similar timepoint, the analyst tells investors in a research note. UBS views the CagriSema’s obesity readout a positive read-through to Lilly, “validating again tirzepatide’s best-in-class profile.” It also

TipRanks yesterday

NONOF

NVO
Jefferies sees Novo dropping ‘at least’ 10%-15% on obesity data

Jefferies analyst Peter Welford says the first headline from Novo Nordisk’s (NVO) Phase III CagriSema obesity data “disappoint” with 20.4% absolute weight loss and patient adherence likely suggesting tolerability concerns. The firm’s buy-side survey suggested most anticipated 25%-27% absolute weight loss with fastrointestinal tolerability to be broadly similar to Wegovy. Jefferies notes its $7.75B peak CagriSema sales are well below the $20B-plus consensus. It expects the Novo shares to be down

TipRanks yesterday

NONOF

NVO
Weight loss seen with Novo’s CagriSema weaker than expected, says BofA

BofA analyst Sachin Jain notes that Novo Nordisk (NVO) shares are down about 25%, which is “what we expected in this data scenario,” as CagriSema weight loss data is not as differentiated compared to Eli Lilly’s (LLY) Zepbound as was expected. Weight loss in the REDEFINE 1 trial at about 20.4% is “essentially in line” with Zepbound at 21%, and not high enough to create a barrier relative to future competition, says the analyst. With that said, the data is still superior to Wegovy and sufficient

TipRanks yesterday

LLY

NONOF
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally

Santa Claus will soon be on his way delivering presents to kids around the world. Three Motley Fool contributors think they've identified fantastic stocks that could be in a good position to benefit from a Santa Claus rally. Here's why they chose AbbVie (NYSE: ABBV), Novo Nordisk (NYSE: NVO), and Vertex Pharmaceuticals (NASDAQ: VRTX).

Motley Fool yesterday

VRTX

NVO
How to Build a High-Quality Passive Income-Producing Real Estate Portfolio for Less Than $250 at a Time

Investing in real estate can be a fantastic way to generate passive income. Rental properties typically throw off more cash than their monthly expenses, enabling investors to pocket the difference as passive income. There are lots of ways to invest in rental properties.

Motley Fool yesterday

O

EXR
Is Now a Good Time to Buy the Dip in Eli Lilly Stock?

Since Eli Lilly reported third-quarter earnings on Oct. 30, its shares have had a prolonged sell-off.

Motley Fool yesterday

LLY

NVO
Rumble Gets $775 Million Investment From Crypto Firm Tether

Video platform Rumble said it entered an agreement for an investment from the cryptocurrency company Tether.

The Wall Street Journal 2 days ago

RUM

RUMBW
Crypto giant Tether invests $775 million in Trump-friendly video service Rumble

Tether's move to buy a large stake in Rumble signals its ambitions to expand both its technological and political ambitions.

Fortune 2 days ago

RUMBW
Novo Nordisk Stock Crashes on Obesity Drug Data. It’s a Win for Eli Lilly.

For more than a year, Novo Nordisk has told the world it expects patients to lose “at least 25%” of their body weight on its experimental drug CagriSema. On Friday, Novo released the results of a large Phase 3 trial of the drug. Patients lost only 22.7% of their body weight, on average, after about a year and a half.

Barrons.com 2 days ago

NVO

LLY

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Trending Tickers

Related News

The Container Store files for Chapter 11 bankruptcy

Elon Musk, RFK Jr., Dr. Oz, and the coming clash over Ozempic

Top trending global stocks of 2024

Singapore Post Shares Slide After CEO Fired Over Whistleblower Report

Donald Trump’s Agenda Has New Enforcers: Charlie Kirk and a Legion of Influencers

Singapore Post fires CEO over handling of whistleblower report

We're Interested To See How IonQ (NYSE:IONQ) Uses Its Cash Hoard To Grow

Is Merck the Next Big Weight-Loss Stock?

The Investing Cult Fueling MicroStrategy’s Ascent: ‘Have Fun Staying Poor’

Palantir Technologies (PLTR) Extends $400M Partnership with U.S. Army to Enhance Data and AI Capabilities

Tilray's CEO Makes a Bold Prediction: Is the Stock a Buy?

Novo obesity data positive for Eli Lilly and Amgen, says UBS

Jefferies sees Novo dropping ‘at least’ 10%-15% on obesity data

Weight loss seen with Novo’s CagriSema weaker than expected, says BofA

3 Fantastic Stocks That Could Enjoy a Santa Claus Rally

How to Build a High-Quality Passive Income-Producing Real Estate Portfolio for Less Than $250 at a Time

Is Now a Good Time to Buy the Dip in Eli Lilly Stock?

Rumble Gets $775 Million Investment From Crypto Firm Tether

Crypto giant Tether invests $775 million in Trump-friendly video service Rumble

Novo Nordisk Stock Crashes on Obesity Drug Data. It’s a Win for Eli Lilly.